Propranolol

Propranolol is a competitive blocker of adrenergic β-receptor sites. It is indicated in: a) The control of hypertension. b) The management of angina pectoris. c) The prevention of re-infarction after recovery from acute myocardial infarction.

d) The control of most forms of cardiac arrhythmias including sinus tachycardia due to thyrotoxicosis, paroxysmal supraventricular tachycardia, atrial fibrillation and atrial flutter, ventricular extrasystoles, ventricular tachycardia and ventricular fibrillation (prophylaxis only), arrhythmias due to digitalis intoxication (if phenytoin cannot be used and no AV-block II or III is present).

e) The adjunctive therapy in thyrotoxicosis. f) The prophylaxis of migraine. g) The management of essential tremor. h) The management of phaeochromocytoma (with an alpha-blocker).

INDICATIONS AND USAGE

Hypertension Propranolol hydrochloride tablets are indicated in the management of hypertension. It may be used alone or used in combination with other antihypertensive agents, particularly a thiazide diuretic. Propranolol hydrochloride is not indicated in the management of hypertensive emergencies.

Angina Pectoris Due to Coronary Atherosclerosis Propranolol hydrochloride tablets are indicated to decrease angina frequency and increase exercise tolerance in patients with angina pectoris. Atrial Fibrillation Propranolol hydrochloride tablets are indicated to control ventricular rate in patients with atrial fibrillation and a rapid ventricular response.

Myocardial Infarction Propranolol is indicated to reduce cardiovascular mortality in patients who have survived the acute phase of myocardial infarction and are clinically stable. Migraine Propranolol is indicated for the prophylaxis of common migraine headache.

HEMANGIOL (propranolol oral solution) is indicated for:

The treatment of proliferating infantile hemangioma requiring systemic therapy:  Life- or function-threatening hemangioma,  Ulcerated hemangioma with pain and/or lack of response to simple wound care measures,  Hemangioma with a risk of permanent scarring or disfigurement.

Treatment should be initiated in infants aged 5 weeks to 5 months. Age for treatment initiation should be corrected in case of prematurity. HEMANGIOL therapy should be initiated and monitored by healthcare professionals experienced in the use of beta-blockers in infants and in the management of infantile hemangioma.

1 Pediatrics  Pediatrics (below 5 weeks of age or below 5 weeks of corrected age for premature babies): No data are available to Health Canada; therefore, Health Canada has not authorized an indication for these pediatric populations.

HEMANGIOL is indicated in the treatment of proliferating infantile haemangioma requiring systemic therapy: • Life- or function-threatening haemangioma, • Ulcerated haemangioma with pain and/or lack of response to simple wound care measures, • Haemangioma with a risk of permanent scars or disfigurement.

2).